-
FDA Regulatory Affairs: A Guide
for Prescription
Drugs
目录
1<
/p>
、药品发展和
FDA
概述
1
、
Overview
of
Drug
Development
and
the FDA
——
Douglas
J. Pisano
药品发展和
F
DA
概述
1.1
Brief
History
of
Drug
Laws
and
1.1
药品法律和监管历史简述
Regulations
Prior to 1902, the U.S. government took
a
在
1902
年之前,美国政府没有
对药品进
hands-off approach to the
regulation of drugs.
行监管。
当时市面上的绝大多数药品都所谓
Many
of
the
drugs
available
were
so-called
的“专利药物”
,因为它们或多或少都是这样
“patent
medicines”
which
were
so
named
宣传的。
即使美国药典(
USP
)在
1820
年成
because each had a more or less
descriptive or
为美国的第一份官方简编,美国的法律法规
patent
name.
No
laws,
regulations
or
或标准仍就一片空白。美国药典为医生和药
standards
existed
to
any
noticeable
extent
剂师提供了剂量和纯度的标准。
even
though
the
United
States
Pharmacopeia
(USP)
became
a
reality
in
1820
as
the
first
official
compendium
of
the
U.S.
The
USP
set
standards
for strength and purity that could be
used
by
physicians
and
pharmacists
who
needed
centralized
guidelines
to
extract,
compound,
and
otherwise
utilize
drug
components
that existed at the time.
However, in 1848, the first American
drug
然而,
1848
年,第一个
美国药品法“药
law,
the
Drug
Importation
Act,
was
enacted
品进口法”颁布。背景是当时正在墨西哥服
when
American
troops
serving
in
Mexico
役的美国军队遭受严重传染,而此时抗疟疾
became
seriously
affected
when
adulterated
药物奎宁被发现是掺假药。这项法律要求对
quinine,
an antimalarial drug, was discovered.
实验室进行检查,拘留,甚至销毁不符合法
This
law
required
laboratory
inspection,
定标准的药品。
后来,在
1902
年,为响应
detention,
and even destruction of drugs that
于由密苏里州圣路易斯的小实验室制造的用
did
not
meet
acceptable
standards.
Later,
in
于破伤风感染的白喉抗毒素,通过了病毒,
1902,
the
Virus,
Serum
and
Toxins
Act
血清和毒素法(
Biologics Control
Act
)
。
背景
(Biologics Control Act)
was passed in response
是
13
p>
名小学生由于接种受污染的血清而死
to
tetanusinfected
diphtheria
antitoxin
which
亡。
当时尚无针对血液制品的纯度或效力的
was
manufactured by a small laboratory in St.
国家标准。此项法律授权公共卫生服务部对
Louis,
MO.
Thirteen
school
children
died
as
a
用于预防或治疗疾病的血清、疫苗和相关生
result
of
the
tainted
serum.
No
national
物制品的州际销售进行许可管理和监督管
standards
were
as
yet
in
place
for
purity
or
理。
potency. The
Act authorized the Public Health
Service
to
license
and
regulate
the
interstate
sale
of
sera,
vaccines,
and
related
biologic
products used to prevent or treat
disease.
This Act also spurred Dr.
Harvey W. Wiley,
chief
chemist
for
the
Bureau
of
Chemistry,
a
branch
of
the
U.S.
Department
of
Agriculture
(US
DA)
and
the
forerunner
for
today’s
U.S.
Food
and
Drug
Administration
(FDA),
to
investigate
the
country’s
foods
and
drugs.
He
established
the
Hygienic
Table,
a
group
of
young
men
who
volunteered
to
serve
as
human
guinea
pigs,
and
who
would
allow
Dr.
Wiley
to
feed
them
a
controlled
diet
laced
with
a
variety
of
preservatives
and
artificial
colors.
More
popularly
known
as
the
“Poison
Squad,”
they
helped
Dr.
Wiley
gather
enough
data
to
prove
that
many
of
America’s
foods
and
drugs
were
adulterated,
the
products’
strength or purity was suspect or
misbranded,
or
products
had
inadequate
or
inaccurate
labeling.
Dr.
Wiley’s
efforts,
along
with
publication
of
Upton
Sinclair’s
The
Jungle
(a
book
revealing
the
putrid
conditions
in
America’s
meat
industry),
were
rewarded
w
hen
Congress passed America’s first food and
drug law in 1906, the Pure Food and
Drug Act
(USPFDA,
also
known
as
the
Wiley
Act).
The
Wiley
Act
prohibited
interstate
commerce
of
misbranded
foods
or
drugs
based
on
their
labeling. It did not affect unsafe
drugs in that
its
legal
authority
would
come
to
bear
only
when
a
product’s
ingredients
were
falsely
labeled.
Even
intentionally
false
therapeutic
claims were not
prohibited.
This
began
to
change
in
1911
with
the
enactment
of
the
Sherley
Amendment
which
intended
to
prohibit
the
labeling
of
medications with false therapeutic
claims that
were intended to defraud
the purchaser. These
amendments,
however,
required
the
government
to
find
proof
of
intentional
labeling fraud.
Later, in 1937, a sentinel event
occurred
that
changed
the
entire
regulatory
picture. Sulfa became the miracle drug
of the
该法案还引发了时任美国农业部
(<
/p>
USDA
)
分支机构化学局首席化学家<
/p>
Harvey
W.
Wiley
博士的关注。
FDA
的前身就是美国农业部<
/p>
(
USDA
)分支机构化学局。
他建立了卫生研究计划,招募了一群年
轻男性
志愿者,
同意参加
Wiley
博士对防
腐剂
和人工色素的试验研究。这就是后来著名的
“毒药队”
,是他们帮助了
Wiley
博士收集了
足够的实验数据,证明了美国的许多食品和
药物掺假,产品的剂量或纯度是可疑的或与
标签不符,或产品标识信息不足或不准确。
Wiley
博士后来写了
Upton
Sinclair's The Jungle
(一本揭示美国肉业肮脏条件的书)
p>
。
1906
年
在国
会通过美国第一个食品和药物法,纯净
食品和药物法案(
USP
FDA
,称为
Wiley Act
)<
/p>
上,
Wiley
博士被嘉奖。
Wiley
法案禁止不符
合标识信息的错误标签食品或药物在州际间
贸易销售。它不影响不安全的药物,因为其
法律权威只有在产品的成分被错误地贴上标
签时才会发生。即使
故意的虚假治疗信息也
没有被禁止。
这在
19
11
年随着“谢利修正案”的颁布
而开始改变,该修订旨在禁止
不符合用药标
识信息的虚假治疗信息,而达到欺骗购买者
的目的
。
然而,修正案要求政府找到有意标
签欺诈的证据。
后来,在
1937<
/p>
年,发生了
一个警示事件,彻底颠覆了美国药品监管。
磺胺类药成为当时的奇迹药物,被用于治疗
许多
危及生命的感染。
但它口感不好,难吞
咽,这导致制药者需要去寻求一个解决方案。
time
and
was
used
to
treat
many
life-threatening
infections.
It
tasted
bad
and
was hard to swallow which led
entrepreneurs
to seek a palatable
solution. S.E. Massingill Co.
of
Bristol,
TN,
developed
what
the
company
thought
was
a
palatable,
raspberry
favored
liquid product.
However, they used diethylene
glycol to
solubilize the sulfa. A volume of 6 gal
of
this
dangerous
mixture,
Elixir
of
Sulfanilamide,
killed
107
people,
mostly
children.
The result was the
passage of one of the
most
comprehensive statutes in the history of
American health law. The Federal Food,
Drug,
and Cosmetic Act of 1938 (FDCA)
repealed the
Sherley
Amendments
and
required
that
all
new
drugs
be
tested
by
their
manufacturers
for safety and
that those tests be submitted to
the
government for marketing approval via the
New
Drug
Application.
The
FDCA
also
mandated
that
drugs
be
labeled
with
adequate
directions
if
they
were
shown
to
have
had
harmful
effects.
In
addition,
the
FDCA
authorized
the
FDA
to
conduct
unannounced
inspections
of
drug
manufacturing
facilities.
Though
amended
many
times
since
1938,
the
FDCA
is
still
the
broad
foundation
for
statutory
authority
for
the FDA as it exists
today.
However,
a
new
crisis
loomed.
Throughout
the
late
1950s,
European
and
Canadian
physicians
began
to
encounter
a
number
of
infants
born
with
a
curious
birth
defect
called
phocomelia,
a
defect
that
resulted in limbs resembling flippers
similar to
those found on seals. These
birth defects were
traced
back
to
mothers
who
had
been
prescribed the drug thalidomide in an
effort to
relieve
morning
sickness
while
pregnant.
The
anufacturer
of
this
drug
applied
for
U.S.
marketing approval of the drug as a
sleep aid.
However,
due
to
the
efforts
of
Dr.
Frances
O.
Kelsey, FDA’s chief
medical officer at the time,
the case
was made that the drug was not safe,
S.E.
Massingill
C
o.
,
Bristol
,
TN
,开发了该公
司认为是一种树莓味的爽口液体产
品。
然
而,他们使用二甘醇溶解磺胺。
<
/p>
6
加仑的这
种危险混合物磺胺药,杀死<
/p>
107
人,大多还
是儿童。
结果是
通过了美国健康法历史上最全面
的法规。
1938
年的《联邦食品,药品和化妆
品法案
(
FDCA
)
》
宣布废除了
Sherley
修正案,
并要求所有新药要由其制造商进行安全性测
试,并且这些测试应通过新药申请
提交政府
进行市场批准。
FDCA<
/p>
还规定,
如果药物被证
明具有有害作用,
那么药物必须贴上相应标
识标签。
此
外,
FDCA
授权
FDA
对药品生产
设施进行突击检查。
< br>虽然自
1938
年以来修
订了很
多次,
但
FDCA
仍然是
FDA
今天广泛存
在的法定权威的基础。
然而,
一个新的危机露头了。
在整个
20
世纪
50
年代后期,欧洲和加拿大医生开始遇
到一些婴儿出生时出现一个
奇怪的出生缺陷
称为
phocomelia
,这是一个缺陷导致四肢类
似于海豹的鳍状物。
这些出生缺陷最终被追
溯到用于缓解孕妇妊娠病的药物沙利度胺。
这种药物的制造商以睡眠辅助作用向美国申
请。
然而,
时任
FDA
的首席医学官
Frances
O.
Kelsey
博士认为,
该药物
不安全,
因此阻止了
其在美国上市。
and
therefore
not
effective
for
release
to
the
U.S. marketplace.
Dr.
Kelsey’s
efforts
and
decisive
work
by
the
U.S.
Congress
resulted
in
yet
another
necessary
amendment
to
the
FDCA
in
1962,
the
Kefauver
–
Harris
Act.
This
act
essentially
closed
many
of
the
loopholes
regarding
drug
safety
in
American
law.
Its
drug
efficacy
amendments
now
required
drug
manufacturers
to
prove
safety
and
efficacy
of
their drug
products, register with the FDA, and
be
inspected at least every 2 years, have their
prescription drug advertising approved
by the
FDA (this authority being
transferred from the
Federal
Trade
Commission),
and
provide
and
obtain
documented
“informed
consent”
to
research
subjects
prior
to
human
trials.
An
increase
in
controls
over
manufacturing
and
testing
was
added
to
determine
drug
effectiveness.
In
an
effort
to
address
these
new
provisions of the act, the FDA contracted
the National Academy of Sciences, along
with
the
National
Research
Council,
to
examine
some
3,400 drug products approved between
1938
and
1962
based
on
safety
alone.
Called
the
Drug
Efficacy
Study
Implementation
Review
of
1966
(DESI),
it
charged
these
organizations
to
make
a
determination
as
to
whether
post-1938
drug
products
were
“effective” for the indications claimed
in their
labeling,
“probably
effective,”
“possibly
effective,” or “ineffective.” Those
products not
deemed “effective” were
either removed from
the marketplace,
reformulated, or sold with a
clear
warning
to
prescribers
that
the
product
was
not deemed effective. Later, in 1972, the
FDA began to examine over-the-counter
(OTC)
drug
products.
Phase
II
of
the
Drug
Efficacy
Amendments
required
the
FDA
to
determine
the efficacy of
OTC drug products. This project
was
much larger in scope than the analysis of
prescription
drugs.
The
1970s
American
consumer
could
choose
from
more
than
300,000
OTC
drug
products.
The
FDA
soon
在
Kelsey
博士和美国国会推动下,
1962
年通过了对
FDCA<
/p>
的另一个必要修正,即
“
Kefauve
r-Harris
法案”
。这一法案基本上完
< br>善了美国法律中关于药物安全的许多方面。
修订案在药物功效方面要求药品制造商
证明
其药品的安全性和有效性,向
FDA
注册,并
至少每
2
年接受检查一次,
由
FDA
批准其处
方药广告(这样权力
现在已经移交到联邦贸
易委员会)
,并在人体试验前向研究对象
提供
并获得记录的“知情同意”
。增加了对生产和
检测的控制,以确定药物的有效性。
为落实如上规定,
FDA
已将与国家科学
院,
携
手国家研究理事会
,
对
1938
年和
1962
年之间批准上市的约
3,400
种药品进行安全
性审查
。
1966
年的药物功效研
究实施审查
(
DESI
)
,
它要求相关组织对
1938
年批准上市之后的药
物进行有效性审查,分为“有效”
,
p>
“可能有
效”
,
“
可能有效”
“或”无效的“。如果不
被认为是”有效“的产品,将采取撤市、重
新配方或明确警告处方中的该产品不是有效<
/p>
的而才可继续销售。
p>
然后,在
1972
年,
FDA
开始对(
OTC
)
药品进行审查。
修订案要求
FDA
需要确定
OTC
药品的有效性。这项计划要比分析处
方药更
加艰巨复杂。
20
世纪
70
年代美国消费者可以选择超过
30
万的非处方药物产品。
FDA
很快意识到,
它没有资源来评估每一
个。因此,建立了由科学家、医疗专业人员
和消费者的咨询小组,负责评估在<
/p>
80
种已确
-
-
-
-
-
-
-
-
-
上一篇:常见剂型英文对照表
下一篇:英国议会制辩论赛规则(BP Debate)